Timing of Immunotherapy Infusions in Triple Negative Breast Cancer
Tests morning versus other timing of pembrolizumab infusions in adults with triple negative breast cancer.
Plain-language title generated from the registry record
Registry title: Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
Key facts
- Where
- Vila Nova de Gaia, PortugalSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06880029, who can take part
Where in Portugal
- Centro Hospitalar Vila Nova de Gaia/EspinhoVila Nova de Gaia, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
- Trial code
- NCT06880029
- Record updated
- 19 March 2025
- Original description
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.Read full original descriptionShow less
Circadian Rhythm Impact on Triple Negative Breast Cancer Response to Neoadjuvant Immunotherapy - a Feasibility Randomized Trial
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
Inclusion: Female sex; Age 18 - 75 years old; Diagnosed with Stage II or III TNBC and candidates for neoadjuvant treatment with ChT+pembrolizumab after multidisciplinary group discussion.
Exclusion: Patients unable to understand or consent to the study; Patients not completing ≥2 cycles of planned neoadjuvant pembrolizumab cycles or ≥50% of planned neoadjuvant ChT cycles; Patients under daily ≥10 mg of prednisolone or equivalent.